We hypothesized that a reduction in mRNA expression of myostatin within a genetic T1DM mouse model would improve skeletal muscle health, resulting in a larger, more insulin sensitive muscle mass. The gene discussed is MSTN; the disease is type 1 diabetes mellitus.